Bon EI¹* and Vihanga BTH²

¹Candidate of Biological Sciences, Associate Professor, Department of Pathological Physiology, Grodno State Medical University, Belarus
²Faculty of Foreign Students-4th year, Grodno State Medical University, Belarus

*Corresponding Author:Bon EI; Candidate of Biological Sciences, Associate Professor, Department of Pathological Physiology, Grodno State Medical University, Belarus.

Received: August 17, 2022; Published: November 23, 2022

Abstract

When a neurological stimulus reaches the end of a nerve fiber, neurotransmitters are produced, and by diffusing across the synapse, they cause the impulse to be transferred to another nerve fiber, a muscle fiber, or some other component. CNS comprises neurotransmitter indicators in the form of genes and proteins that are expressed uniquely in various cells. The major neurotransmitter indicators' neurological, developmental, and pathological functions are demonstrated in this article.

Keywords: Neurotransmitters; Schizophrenia; Membrane Transporters; CB Proteins; Neuropeptides; NT Receptors; Matrix Proteins

References

1. “Neurotransmitters - ScienceDirect (2002).
2. Abeles M. “Corticonics: Neural Circuits of the Cereb Cortex”. Cambridge University Press (1991).
3. Van Liefferinge J., et al. “Are Vesicular Neurotransmitter Transporters Potential Treatment Targets for Temporal Lobe Epilepsy?” Frontiers in Cellular Neuroscience 7 (2013): 139.
4. Rees CL., et al. “Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance”. Current Medicinal Chemistry 28 (2017): 3077-3103.
5. Somogyi J., et al. “GABAergic Basket Cells Expressing Cholecystokinin Contain Vesicular Glutamate Transporter Type 3 (VGLUT3) in Their Synaptic Terminals in Hippocampus and Isocortex of the Rat”. European Journal of Neuroscience 3 (2004): 552-569.
6. Heizmann CW and Braun K. “Changes in Ca 2+-Binding Proteins in Human Neurodegenerative Disorders”. Trends in Neurosciences 7 (1992): 259-264.
7. Schurmans S., et al. “Impaired Long-Term Potentiation Induction in Dentate Gyrus of Calretinin-Deficient Mice”. Proceedings of the National Academy of Sciences of the United States of America 19 (1997): 10415-10420.
8. Alexandrescu S., et al. “Role of Calretinin Immunohistochemical Stain in Evaluation of Hirschsprung Disease: An Institutional Experience”. International Journal of Clinical and Experimental Pathology 12 (2013): 2955-2961.
9. Marchevsky AM. “Application of Immunohistochemistry to the Diagnosis of Malignant Mesothelioma”. Archives of Pathology and Laboratory Medicine3 (2018): 397-401.
10. Tóth K and Maglóczky Z. “The Vulnerability of Calretinin-Containing Hippocampal Interneurons to Temporal Lobe Epilepsy”. Frontiers in Neuroanatomy 8 (2014): 100.
11. Celio MR and Heizmann CW. “Calcium-Binding Protein Parvalbumin Is Associated with Fast Contracting Muscle Fibres”. Nature5866 (1982): 504-506.
12. Nakazawa K., et al. “GABAergic Interneuron Origin of Schizophrenia Pathophysiology”. Neuropharmacology 3 (2012): 1574-1583.
13. Guentchev M., et al. “Distribution of Parvalbumin-Immunoreactive Neurons in Brain Correlates with Hippocampal and Temporal Cortical Pathology in Creutzfeldt-Jakob Disease”. Journal of Neuropathology and Experimental Neurology 10 (1997): 1119-1124.
14. Grove KL., et al. “Novel Expression of Neuropeptide Y (NPY) mRNA in Hypothalamic Regions during Development: Region-Specific Effects of Maternal Deprivation on NPY and Agouti-Related Protein mRNA”. Endocrinology11 (2001): 4771-4776.
15. Kudo T., et al. “Vasoactive Intestinal Peptide Produces Long-Lasting Changes in Neural Activity in the Suprachiasmatic Nucleus”. Journal of Neurophysiology 5 (2013): 1097-1106.
16. Hermanstyne TO., et al. “Distinct Firing Properties of Vasoactive Intestinal Peptide-Expressing Neurons in the Suprachiasmatic Nucleus”. Journal of Biological Rhythms 1 (2016): 57-67.
17. Said SI. “Vasoactive Intestinal Peptide”. Advance Metabolic Disorders 11 (2013): 369-390.
18. DiCicco-Bloom E. “Region-Specific Regulation of Neurogenesis by VIP and PACAP: Direct and Indirect Modes of Action”. Annals of the New York Academy of Sciences 1 (1996): 244-256.
19. Hill JM. “Vasoactive Intestinal Peptide in Neurodevelopmental Disorders: Therapeutic Potential”. Current Pharmaceutical Design 11 (2001): 1079-1089.
20. De Lanerolle NC., et al. “Vasoactive Intestinal Polypeptide and Its Receptor Changes in Human Temporal Lobe Epilepsy”. Brain Research2 (1995): 182-193.
21. Parent JM., et al. “Prolonged Seizures Increase Proliferating Neuroblasts in the Adult Rat Subventricular Zone-olfactory Bulb Pathway”. Journal of Neuroscience 8 (2002): 3174-3188.
22. Gerber U anb Gähwiler BH. “The metabotropic glutamate receptors”. Springer; 1994. Modulation of Ionic Currents by Metabotropic Glutamate Receptors in the CNS (1994): 125-146.
23. Glaum SR and Miller RJ. “The Metabotropic Glutamate Receptors”. Springer; 1994. Acute Regulation of Synaptic Transmission by Metabotropic Glutamate Receptors (1994): 147-172.
24. Julio-Pieper M., et al. “Exciting Times beyond the Brain: Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues”. Pharmacological Reviews 1 (2011): 35-58.
25. Skerry TM and Genever PG. “Glutamate Signalling in Non-Neuronal Tissues”. Trends in Pharmacological Sciences 4 (2001): 174-181.
26. Chenu C., et al. “Glutamate Receptors Are Expressed by Bone Cells and Are Involved in Bone Resorption”. Bone4 (1998): 295-299.
27. Newcombe J., et al. “Glutamate Receptor Expression in Multiple Sclerosis Lesions”. Brain Pathology 1 (2008): 52-61.
28. Cha JHJ., et al. “Altered Brain Neurotransmitter Receptors in Transgenic Mice Expressing a Portion of an Abnormal Human Huntington Disease Gene”. Proceedings of the National Academy of Sciences of the United States of America 11 (1998): 6480-6485.
29. Shin SS., et al. “Oncogenic Activities of Metabotropic Glutamate Receptor 1 (Grm1) in Melanocyte Transformation”. Pigment Cell and Melanoma Research 3 (2008): 368-378.
30. Nyíri G., et al. “Input-Dependent Synaptic Targeting of α2-Subunit-Containing GABAA Receptors in Synapses of Hippocampal Pyramidal Cells of the Rat”. European Journal of Neuroscience 3 (2001): 428-442.
31. Klausberger T., et al. “Cell Type-and Input-Specific Differences in the Number and Subtypes of Synaptic GABAA Receptors in the Hippocampus”. The Journal of Neuroscience 7 (2002): 2513-2521.
32. Pawelzik H., et al. “Physiological and Morphological Diversity of Immunocytochemically Defined Parvalbumin-and Cholecystokinin-Positive Interneurones in CA1 of the Adult Rat Hippocampus”. Journal of Comparative Neurology 4 (2002): 346-367.
33. Erdö SL and Wolff JR. “γ-Aminobutyric Acid Outside the Mammalian Brain”. Journal of Neurochemistry 2 (1990): 363-372.
34. Akinci MK and Schofield PR. “Widespread Expression of GABA A Receptor Subunits in Peripheral Tissues”. Neuroscience Research 2 (1999): 145-153.
35. Möhler H. “Pharmacology of GABA and Glycine Neurotransmission”. Springer; 2001. Functions of GABAA-Receptors: Pharmacology and Pathophysiology (2001): 101-116.
36. Gaspar P., et al. “The Developmental Role of Serotonin: News from Mouse Molecular Genetics”. Nature Reviews Neuroscience 12 (2003): 1002-1012.
37. Buckley NE., et al. “Expression of the CB 1 and CB 2 Receptor Messenger RNAs during Embryonic Development in the Rat”. Neuroscience4 (1997): 1131-1149.
38. Henry JL and Substance P. “Inflammatory Pain: Potential of Substance P Antagonists as Analgesics”. Agents Actions 41 (1992): 75-87.
39. De Felipe C., et al. “Altered Nociception, Analgesia and Aggression in Mice Lacking the Receptor for Substance P”. Nature 6674 (1998): 394-397.
40. Nichols ML., et al. “Transmission of Chronic Nociception by Spinal Neurons Expressing the Substance P Receptor”. Science5444 (1999): 1558-1561.
41. Zubrzycka M and Janecka A. “Substance P: Transmitter of Nociception (Minireview)”. Endocrine Regulations 4 (2000): 195-202.
42. Sternini C., et al. “Cellular Sites of Expression of the Neurokinin-1 Receptor in the Rat Gastrointestinal Tract”. The Journal of Comparative Neurology 4 (1995): 531-540.
43. Karagiannides I., et al. “Substance P (SP)-Neurokinin-1 Receptor (NK-1R) Alters Adipose Tissue Responses to High-Fat Diet and Insulin Action”. Endocrinology 6 (2011): 2197-2205.
44. Maurin JC., et al. “Expression and Localization of Reelin in Human Odontoblasts”. Matrix Biology 5 (2004): 277-285.
45. Rawlinson SC., et al. “Adult Rat Bones Maintain Distinct Regionalized Expression of Markers Associated with Their Development”. PLoS One12 (2006): e8358.
46. Guidotti A., et al. “Decrease in Reelin and Glutamic Acid decarboxylase67 (GAD67) Expression in Schizophrenia and Bipolar Disorder: A Postmortem Brain Study”. Archives Of General Psychiatry 11 (2000): 1061-1069.
47. Wirths O., et al. “Reelin in Plaques of β-Amyloid Precursor Protein and Presenilin-1 Double-Transgenic Mice”. Neuroscience Letters 3 (2001): 145-148.
48. Meyer-Lindenberg A., et al. “Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia”. Nature Neuroscience 5 (2002): 267-271.
49. Howes O and Kapur S. “The dopamine hypothesis of schizophrenia: version III- the final common pathway”. Schizophrenia Bulletin 35 (2009): 549-562.
50. Schoonover K., et al. “Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra”. Neuropsychopharmacology 42 (2017): 540-550.
51. Perez-Costas E., et al. “Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra”. Frontiers in Psychiatry 9 (2012): 31.

Citation

Citation: Bon EI and Vihanga BTH. “Markers of Neurotransmitters: A Review”Acta Scientific Orthopaedics 5.12 (2022): 177-183.

Copyright

Copyright: © 2022 Bon EI and Vihanga BTH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.